



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited (“Chi-Med”)  
(AIM: HCM)**

**Director’s Shareholding**

**London: Wednesday, 30 May 2012:** Chi-Med received notification on 30 May 2012 that Mr Christopher Nash, Independent Non-executive Director of Chi-Med, transferred 18,000 ordinary shares of US\$1.00 each in Chi-Med (the “Shares”) on 29 May 2012 to his own Self Invested Pension Plan account at a price of GBP4.275.

Following this transfer, the beneficial interest of Mr Nash remains unchanged at 18,000 Shares, representing approximately 0.03% of the current issued share capital of Chi-Med.

**Ends**

**Enquiries**

<b>Chi-Med</b> Christian Hogg, CEO	Telephone: +852 2121 8200
<b>Citigate Dewe Rogerson</b> Anthony Carlisle David Dible	Telephone: +44 20 7638 9571 Mobile: +44 7973 611 888 Mobile: +44 7967 566 919
<b>Lazard &amp; Co., Limited</b> Paul Gismondi Nick Fowler	Telephone: +44 20 7187 2000

**About Chi-Med**

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited.